Home » Newsletters » BioWorld Asia

BioWorld Asia

June 14, 2000

View Archived Issues

European Biotech Fund Raising Lags, But Products Are Coming

Canada Invests In Virtual Medical Health Institutes

GenOdyssee Gathers $8.6M In Financing For SNP Effort

Taiwan Firm Invests $6.2 Million In Progen For Molecule Development

Peptide Therapeutics Has Positive Results In Phase III Arilvax Trial

Oxford, Aventis Extend Agreement In Cardiovascular Gene Therapy

British Biotech Pares 80 Jobs, With Saved Funds To Push Development

Scotia Gets Boost From Journal Backtracking On Foscan Data

European Industrialists Call For More Backing For Biotech

Transghne Receives $1 Million Milestone from Schering-Plough

ProChon, MorphoSys Form Deal Around Antibody Library

Genset Raises EUR49 Million In Private Placement Of Bonds

ICH Mulls Gene Therapy Rules, Common Application Format

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...